The Engineered Lysin, CF-370, is Active Against Antibiotic-Resistant Gram-Negative Pathogens In vitro and Synergizes with Meropenem in Experimental Pseudomonas aeruginosa Pneumonia

By sjmartinez • February 18, 2024

Sauve K, Watson A, Oh JT, Swift S, Vila-Farres X, Abdelhady W, Xiong YQ, LeHoux D, Woodnutt G, Bayer AS, Schuch R. The Engineered Lysin, CF-370, is Active Against Antibiotic-Resistant Gram-Negative Pathogens In vitro and Synergizes with Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. J Infect Dis. 2024 Feb 15:jiae027. doi: 10.1093/infdis/jiae027. Epub ahead of print. PMID: 38366561.

Tags: ESKAPE pathogens, Harbor UCLA, Infectious Diseases, Lysin, multidrug-resistance, pneumonia, pseudomonas aeruginosa, Publications, synergy

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]

Effect of colchicine on progression of known coronary atherosclerosis in patients with stable coronary artery disease: EKSTROM randomized placebo controlled trial

Budoff MJ, Bhandari M, Iskander B, Ghanem AK, Kinninger A, Stark J, Garikapati V, Chilukuri S, Hankil V, Krishnan S, Punnanithinont N, Ichikawa K, Kambalapalli[...]

Disease Modification and Progression in Pre-Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Workshop Report

Putcha N, Bhatt SP, Bon J, Christenson SA, Han MK, Krishnan JA, Martinez FJ, Casaburi R, Crapo JD, Curtis JL, Diette GB, Dransfield MT, Eakin[...]